Moderna sues Pfizer, BioNTech over patents behind Covid-19 vaccine

Moderna said on Friday that Pfizer and BioNTech's vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

Moderna vaccine
Photo: Shutterstock
AP Washington
1 min read Last Updated : Aug 26 2022 | 11:06 PM IST

COVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna's technology in order to make their own vaccine.

Moderna said on Friday that Pfizer and BioNTech's vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, Spikevax.

The company filed patent infringement lawsuits in both US federal court and a German court.

A Pfizer spokeswoman declined to comment, saying the company had not been served with a copy of the litigation.

Moderna and Pfizer's two-shot vaccines both use mRNA technology to help patients fight the coronavirus.

The mRNA vaccines work by injecting a genetic code for the spike protein that coats the surface of the coronavirus. That code, the mRNA, is encased in a little ball of fat, and instructs the body's cells to make some harmless spike copies that train the immune system to recognise the real virus.

Moderna CEO Stephane Bancel said in a prepared statement that the vaccine developer pioneered that technology and invested billions of dollars in creating it.

The company said it believes its rivals' vaccine infringes on patents Moderna filed between 2010 and 2016.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :PfizerCoronavirus Vaccine

First Published: Aug 26 2022 | 8:28 PM IST

Next Story